Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-CAR T Cell Consolidation After Haploidentical HCT for Relapsed/Refractory CD19+ ALL and Lymphoma
NCT07257419Phase 1Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2031
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19-CAR.CD45RA-negative T-cells in acute lymphoblastic leukemia (ALL) and lymphoma, sponsored by St. Jude Children's Research Hospital. Primary endpoints: Safety of combining CD19-CAR(Mem) T cells after TCRαβ+/CD19 depleted haploidentical donor transplantation and Feasibility of combining CD19-CAR(Mem) T cells after TCRαβ+/CD19 depleted haploidentical donor transplantation. Started Oct 2026; status: recruiting.
02
Drugs
CD19-CAR.CD45RA-negative T-cells
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoma
Beyond the preview
Go deeper on NCT07257419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07257419.